Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 5/20 | 0.37 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 4/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.35 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.35 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.35 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.35 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.35 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.35 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.35 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2512455 | 1.00 | IDO1 (0.40) | IDO1TDO2MAPTGPBAR1TACR1 | |
| Hydrochloric Acid SCHEMBL3138452 | 1.00 | IDO1 (0.40) | IDO1TDO2MAPTGPBAR1TACR1 | |
| SCHEMBL2365906 | 0.98 | MAPT (0.40) | IDO1TDO2MAPTGPBAR1TACR1 | |
| SCHEMBL3154962 | 0.98 | MAPT (0.40) | IDO1TDO2MAPTGPBAR1TACR1 | |
| SCHEMBL1432906 | 0.98 | MAPT (0.40) | IDO1TDO2MAPTGPBAR1TACR1 | |
| SCHEMBL15215514 | 0.88 | RAPGEF4 (0.41) | MAPTGPBAR1TACR1HTR2ASLC6A4 | |
| SCHEMBL17924527 | 0.88 | HTR2A (0.35) | IDO1TDO2MAPTGPBAR1TACR1 | |
| SCHEMBL15215511 | 0.88 | HTR2A (0.35) | IDO1TDO2MAPTGPBAR1TACR1 | |
| SCHEMBL15211765 | 0.88 | RAPGEF4 (0.41) | MAPTGPBAR1TACR1HTR2ASLC6A4 | |
| SCHEMBL20530516 | 0.87 | MAPT (0.41) | MAPTGPBAR1TACR1ALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117562-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2117535-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | GLAXO GROUP LIMITED | 2010-12-16 | — | — | US | disclosed |
| US-20100152446-A1 | Piperidine Derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| EP-1921064-B1 | Pharmaceutical composition | GLAXO GROUP LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100081667-A1 | Chemical Compounds | ALVARO GIUSEPPE | 2010-04-01 | — | — | US | disclosed |
| US-7652012-B2 | Orvepitant maleate; potent and specific antagonists of tachykinins, including substance P and other neurokinins; anxioltic and antidepressant | GLAXO GROUP LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7648990-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| CN-1483025-A | Chemical compounds | — | 2004-03-17 | — | — | CN | disclosed |
| US-20040014770-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | US | disclosed |
| WO-2004005256-A2 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003066635-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066621-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066589-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| EP-1326832-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002032867-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | TACR1 19/4885HTR2A 179/4885SLC6A4 306/4885 |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | TACR2, TACR1, KCNH3 | TACR1 2/4885HTR2A 532/4885SLC6A4 412/4885 |
| US-20040014770-A1 | Chemical compounds | HCK, KCNK4, GRK4 | TACR1 188/4885HTR2A 1962/4885SLC6A4 890/4885 |
| US-20100152446-A1 | Piperidine Derivatives | NPSR1, NPY5R, NPY4R | TACR1 5/4885HTR2A 402/4885SLC6A4 316/4885 |
| US-20100081667-A1 | Chemical Compounds | OPRL1, OPRK1, OPRM1 | TACR1 53/4885HTR2A 575/4885SLC6A4 642/4885 |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | HTR1A, TPH1, HTR5A | TACR1 7/4885HTR2A 15/4885SLC6A4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.